APM

Aptorum Group Ltd

Add to Watchlist

Advanced Chart

1.810

+0.06(3.429%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.8205

Open

1.750

VWAP

1.78

Vol

120.74K

Mkt Cap

12.93M

Low

1.720

Amount

214.47K

EV/EBITDA(TTM)

Total Shares

5.47M

6.87M

EV/OCF(TTM)

P/S(TTM)

Aptorum Group Limited is a United Kingdom-based clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The Company's pipeline is also enriched through the co-development of PathsDx Test, a novel molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore's Agency for Science, Technology and Research.

Valuation Metrics

The current forward P/E ratio for Aptorum Group Ltd (APM.O) is 0.03, compared to its 5-year average forward P/E of -1.65. For a more detailed relative valuation and DCF analysis to assess Aptorum Group Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.65

Current PE

0.03

Overvalued PE

0.03

Undervalued PE

-3.34

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.70

Current EV/EBITDA

0.31

Overvalued EV/EBITDA

6.71

Undervalued EV/EBITDA

-14.10

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

25.38

Current PS

0.05

Overvalued PS

60.04

Undervalued PS

-9.28